IAS (International AIDS Society) Conference

The Latest

MK-8591: Further Compelling Early Results for Both Treatment and Prevention

Two interesting early studies on the investigational NRTI MK-8591 (EFdA) were presented at IAS 2017. This compound is notable for a very high potency, a long-half life and the potential for use both as HIV treatment and for HIV prevention.

By Simon Collins for HIV i-Base

HIV Pipeline Drugs: IAS 2017 Update

A review of HIV drugs in development that summarizes the most exciting new research over the previous year.

By Simon Collins for HIV i-Base

Phase 3 Results With Bictegravir -- A New Integrase Inhibitor Combined With FTC/TAF

Two studies presented at IAS 2017 showed bictegravir to be very similar in efficacy to dolutegravir with slight differences in the formulations linked to the background NRTIs in the fixed-dose combinations.

By HIV i-Base

HIV Remission News From IAS 2017

Treatment Action Group's Richard Jefferys provides a comprehensive overview of HIV remission presentations at the 9th International AIDS Society Conference on HIV Science.

By Richard Jefferys for Treatment Action Group

HIV Antiretroviral Therapy: Past, Present and Future

In the last two decades, antiretroviral therapy has dramatically improved the health of people living with HIV. Let’s take a brief look at the past and present before we look forward to HIV treatment in 2020.

By Sony Salzman

Joel Gallant on Tenofovir Alafenamide (TAF) and Aging HIV Providers (Video)

In this interview, Joel E. Gallant, M.D., M.P.H., discusses new HIV drugs in the pipeline and the lack of young people becoming HIV care specialists.

By Barbara Jungwirth

Asier Sáez-Cirión on Functional HIV Cure in French Teenager (Video)

Asier Sáez-Cirión, Ph.D., of the Institut Pasteur in Paris, sits down with IFARA to talk about his case study of a French teenager who has achieved HIV remission for 12 years.

By Barbara Jungwirth

Sharon Lewin on Finding a Cure for HIV (Video)

A long-term aspirational goal is the elimination of HIV. In 1996, highly active antiretroviral therapy was thought to constitute a cure. Then latency was discovered to be a cure barrier. Today, achieving long-term remission of the virus is considered...

By Barbara Jungwirth

One Size May Not Fit All in HIV Cure Research

In these formative stages of HIV cure research, scientists have largely been focused on the challenges presented by the virus and the immune system, leaving considerations of diverse populations of HIV-positive people aside. That is beginning to chan...

By Rowena Johnston, Ph.D., for amfAR, The Foundation for AIDS Research

Long-Term HIV Remission Case Raises More Questions Than Answers

While no one is calling this case a cure, it does raise some interesting questions about "post-treatment control" and may provide clues about how to achieve a functional cure or long-term HIV remission.

By Liz Highleyman for BETA